Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Rathnapala (Welisara, Sri Lanka), L. Wing (Oxford, United Kingdom), R. Benamore (Oxford, United Kingdom), J. David (Oxford, United Kingdom), R. Hoyles (Oxford, United Kingdom). A single center experience of rituximab for anti synthetase syndrome associated interstitial lung disease (ASS-ILD). 1367

Member's Comments

No comment yet.

Related content which might interest you: Interstitial lung disease (ILD) associated with anti-PM/Scl and anti-aminoacyl-tRNA synthetase (ARS) autoantibodies: a similar condition? Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Antisynthetase syndrome (AS) in patients with diffuse interstitial lung disease (ILD) Source: International Congress 2015 – Connective tissue disorders Year: 2015 Dermato-pulmonary syndrome associated with MDA-5 antibodies Source: International Congress 2016 – Dealing with the complexity of critically-ill patients Year: 2016 A review of patients following a diagnosis of unclassified interstitial lung disease (ILD) at a tertiary centre Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Rituximab therapy for interstitial lung disease in patients with antisynthetase syndrome Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Detection of anti DFS70 antibodies in patients with interstitial lung disease (ILD) with and without connective tissue disease (CTD) Source: International Congress 2016 – Connective tissue disorders Year: 2016 Nine cases of interstitial lung disease associated with anti-CADM140 antibody positive dermatomyositis Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 Interstitial lung disease (ILD) in patients with polymyositis/dermatomyositis (PM/DM): clinical features and response to treatment in 6 cases Source: Eur Respir J 2001; 18: Suppl. 33, 528s Year: 2001 Telomere (TL) shortening is associated with disease severity in scleroderma (SSC) associated interstitial lung disease (ILD) Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside Year: 2012 Serum anti DFS70 antibody titer and lung functional impairment in patients with interstitial lung disease (ILD) Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Rituximab in severe, progressive interstitial lung disease Source: International Congress 2016 – Connective tissue disorders Year: 2016 Rituximab treatment of a case of anti-syntetase syndrome with severe interstitial lung disease and acute respiratory failure Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010 Clinical features and CT findings of anti-Jo-1 antibody positive interstitial lung disease with or without polymyositis and dermatomyositis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Dermato-pulmonary syndrome associated with MDA-5 antibodies: Report of the first French series Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Clinical manifestation and prognostic factor in anti-aminoacyl-tRNA synthetase autoantibodies-associated interstitial lung disease Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 The role of secondary pulmonary hypertension (SPH) in the limited exercise tolerance of patients with interstitial lung disease (ILD) Source: Eur Respir J 2005; 26: Suppl. 49, 560s Year: 2005 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Utility of myositis related antibodies in interstitial lung disease and suspected autoimmunity. Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 A multicentre evaluation of inter-multidisciplinary team agreement for predicted disease behaviour and management strategy in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016